Gene Silencing Therapeutics Market Global Report 2026

The gene silencing therapeutics market size has grown rapidly in recent years. It will grow from $4 billion in 2025 to $4.64 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to growing prevalence of genetic disorders, increasing investment in molecular medicine research, rising demand for targeted therapeutic approaches, expanding clinical success of RNA based therapies, increasing focus on rare disease treatment development.

The gene silencing therapeutics market size is expected to see rapidly grown in the next few years. It will grow to $8.49 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to advancing commercialization of gene silencing therapeutics, growing pipeline of precision genetic medicines, increasing regulatory approvals for novel gene therapies, expanding application across oncology and neurological disorders, rising adoption of personalized medicine strategies. Major trends in the forecast period include increasing adoption of RNA interference based therapeutics, growing development of antisense oligonucleotide treatment platforms, rising focus on targeted gene expression regulation for rare diseases, expansion of advanced delivery technologies for gene silencing therapeutics, increasing clinical research activity in next generation gene silencing therapies.

The growing focus on personalized medicine is expected to propel the growth of the gene silencing therapeutics market going forward. Personalized medicine refers to a healthcare approach that customizes medical treatment based on an individual’s genetic profile, biomarkers, and specific disease characteristics to enhance treatment effectiveness and clinical outcomes. The increasing focus on personalized medicine is driven by advancements in genetic and molecular profiling technologies that enable tailored treatments based on individual patient characteristics. Gene-silencing therapeutics support personalized medicine by selectively targeting disease-causing genes based on an individual’s genetic profile, enabling more precise treatment with improved effectiveness and fewer side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the gene silencing therapeutics market.

Major companies operating in the gene silencing therapeutics market are adopting advanced RNA delivery platforms, such as ligand-conjugated siRNA technologies, to improve tissue-specific targeting and enhance therapeutic precision for genetic and renal diseases. Ligand-conjugated siRNA technologies refer to specialized RNA delivery approaches that attach targeting ligands to small interfering RNA molecules to enable receptor-mediated uptake and selective gene silencing in specific tissues or cell types. For instance, in June 2025, Judo Bio, Inc., a US-based biotechnology company, launched with $100 million in Series A financing led by Atlas Venture, TCG, and Droia Ventures to advance precision genetic medicines targeting kidney diseases. The company introduced its STRIKE (Selectively Targeting RNA Into Kidney) platform, a ligand-conjugated siRNA delivery technology engineered for receptor-mediated uptake into kidney cell types, enabling selective gene silencing in renal tissues. The platform’s initial megalin-STRIKER programs are designed to deliver small interfering RNA therapeutics to proximal tubule cells in the kidney to silence mRNA expression of solute carrier proteins associated with systemic and renal diseases.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed amount. Through this acquisition, Novartis AG aimed to strengthen its gene silencing therapeutics pipeline by integrating DTx Pharma Inc.’s proprietary FALCON RNA delivery platform to expand the development of RNAi-based therapies for neurological and neuromuscular diseases. DTx Pharma Inc. is a US-based biotechnology company specializing in RNA-based therapeutics, particularly small interfering RNA (siRNA) technologies designed to silence disease-causing genes.

Major companies operating in the gene silencing therapeutics market are Novartis AG; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Silence Therapeutics plc; Wave Life Sciences Ltd.; ProQR Therapeutics N.V.; Dyne Therapeutics Inc.; Stoke Therapeutics Inc.; Arbutus Biopharma Corporation; PepGen Inc.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Benitec Biopharma Inc.; ADARx Pharmaceuticals Inc.; Tune Therapeutics Inc.; Sylentis S.A.; Isarna Therapeutics GmbH; City Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Novo Nordisk; Moderna Inc.; BioNTech SE; Sanofi.

North America was the largest region in the gene silencing therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene silencing therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene silencing therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene silencing therapeutics market consists of revenues earned by entities by providing services such as RNA interference (RNAi) therapy development, antisense oligonucleotide therapy services, gene expression suppression solutions, target gene validation, therapeutic RNA design, drug delivery optimization, clinical development services, and precision medicine support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene silencing therapeutics market also includes sales of microfluidic delivery systems, electroporation devices, lipid nanoparticle formulation equipment, and automated nucleic acid synthesizers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The gene silencing therapeutics market research report is one of a series of new reports that provides gene silencing therapeutics market statistics, including gene silencing therapeutics industry global market size, regional shares, competitors with a gene silencing therapeutics market share, detailed gene silencing therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gene silencing therapeutics industry. This gene silencing therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.